Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.37 | 0.03 | 0.02 |
| FCF Yield | -32.45% | -138.13% | -270.42% | -63.67% |
| EV / EBITDA | -3.04 | -0.75 | -0.57 | -1.41 |
| Quality | ||||
| ROIC | -33.08% | -321.43% | -59.96% | -58.38% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -85.92% |
| Cash Conversion Ratio | 1.04 | 0.81 | 0.89 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -71.00% |
| Free Cash Flow Growth | -15.77% | 3.88% | 22.14% | 51.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | -0.16 | -0.21 | -0.03 |
| Interest Coverage | -26.03 | -15.42 | -16.34 | -30.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,911.48 | -37.22 | -533.32 | -396.85 |